Shandong Xinhua Pharma Initiates Phase II Study of OAB-14 for Alzheimer’s Disease
China-based Shandong Xinhua Pharmaceutical Co., Ltd (SHE: 000756) announced the initiation of a Phase II...
SHE: 000756
Phase I Success for Shandong Xinhua’s OAB-14, Advancing to Phase IIa in Alzheimer’s Therapy
Shandong Xinhua Pharmaceutical Co., Ltd, a Chinese pharmaceutical company listed in Shenzhen (SHE: 000756), has...
Xinhua Pharma’s OAB-14 Receives NMPA Approval for Phase I Alzheimer’s Study
China-based Shandong Xinhua Pharmaceutical Co., Ltd (SHE: 000756) has announced receiving approval from the National...